Intersection · Evidence × effect size
Evidence topics tagged effect size
Topics in Evidence carrying the tag effect size. Magnitude, not just direction or significance.
84 topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Journal club: indirect comparison between two programmes, defended and attacked
Journal club: indirect comparison between two programmes, defended and attacked Writing it up because I had to work it out twice and would rather nobody else did. Comparing SUSTAIN 6 ( N Engl J Med , 2016)…
|
+122 | 131 | 5.2k | just now |
|
Journal club: LEADER as the historical anchor
Journal club: LEADER as the historical anchor Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med , 2021) with SURMOUNT-4 ( JAMA , 2024) and…
|
+103 | 110 | 8.1k | 2h |
|
When a network meta-analysis is defensible and when it is not
When a network meta-analysis is defensible and when it is not I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing SUSTAIN 6 ( N Engl J Med , 2016) with LEADER (…
|
2 | 27k | 4h | |
|
Journal club: STEP 8 and the fairness of the comparator dose — a second dataset
Posting this under the heading it deserves: Journal club: STEP 8 and the fairness of the comparator dose — a second dataset Everything below is what sits behind that. Session topic: SURPASS-2 ( N Engl J Med ,…
|
+18 | 22 | 656 | 13h |
|
Journal club: semaglutide in MASH, and surrogate endpoints
Posting this under the heading it deserves: Journal club: semaglutide in MASH, and surrogate endpoints Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with SURMOUNT-2 (…
|
+24 | 28 | 17k | 15h |
|
Journal club: STEP 1 and the treatment-policy estimand — does this still hold?
Asking directly, because I could not find a straight answer: Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Comparing STEP 2 ( Lancet , 2021) with SURPASS-2 ( N Engl J Med ,…
|
+70 | 76 | 4.8k | 15h |
|
A structured critique template this community uses — a second dataset
On the subject in the title: A structured critique template this community uses — a second dataset Working notes rather than a conclusion. Session topic: SELECT ( N Engl J Med , 2023). Please read it before…
|
+47 | 51 | 16k | 15h |
|
A critique that turned out to be unfair, retracted by its author
Posting this under the heading it deserves: A critique that turned out to be unfair, retracted by its author Everything below is what sits behind that. Session topic: SURMOUNT-4 ( JAMA , 2024). Please read it…
|
+34 | 38 | 20k | 17h |
|
Revisiting: What pooling buys you and what it destroys
On the subject in the title: Revisiting: What pooling buys you and what it destroys Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before posting; the…
|
+97 | 107 | 4k | 19h |
|
Journal club: the CagriSema phase 2 combination paper
On the subject in the title: Journal club: the CagriSema phase 2 combination paper Working notes rather than a conclusion. I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited in support of a claim I do not…
|
2 | 329 | 21h | |
|
Immortal time bias in a claims-database study — one year on
Posting this under the heading it deserves: Immortal time bias in a claims-database study — one year on Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med , 2021) with SURMOUNT-1 (…
|
+41 | 46 | 3.7k | 22h |
|
Journal club: what we got wrong in an earlier session
On the subject in the title: Journal club: what we got wrong in an earlier session Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before posting; the…
|
+114 | 125 | 2.5k | 23h |
|
Risk-of-bias tools and the judgement they conceal — does this still hold?
Risk-of-bias tools and the judgement they conceal — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 ( N Engl J Med , 2021)…
|
+26 | 30 | 5.8k | 23h |
|
Pooling trials with different estimands
On the subject in the title: Pooling trials with different estimands Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with SURMOUNT-1 ( N Engl J Med , 2022) and finding the…
|
+120 | 132 | 2.3k | 1d |
|
A structured critique template this community uses
A structured critique template this community uses — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURPASS-4 ( Lancet , 2021) and finding the…
|
2 | 18k | 1d | |
|
Selection into a registry and what it does to the estimate — a second dataset
Posting this under the heading it deserves: Selection into a registry and what it does to the estimate — a second dataset Everything below is what sits behind that. Session topic: SURMOUNT-4 ( JAMA , 2024).…
|
+28 | 32 | 1.3k | 1d |
|
[2026 update] Journal club: what we got wrong in an earlier session
Journal club: what we got wrong in an earlier session — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think it…
|
+5 | 9 | 4.2k | 1d |
|
Publication bias detection and its low power
On the subject in the title: Publication bias detection and its low power Working notes rather than a conclusion. I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited in support of a claim I do not think it…
|
2 | 3.2k | 1d | |
|
Revisiting: How this community labels and discusses unrefereed work
Revisiting: How this community labels and discusses unrefereed work Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited in…
|
+31 | 35 | 7k | 1d |
|
Journal club: SUSTAIN 6 and its retinopathy signal
On the subject in the title: Journal club: SUSTAIN 6 and its retinopathy signal Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I do not think it…
|
+110 | 122 | 46k | 1d |
|
A pooled estimate that changed when one trial was added
A pooled estimate that changed when one trial was added — setting out what I have, and where I think it stops being reliable. Session topic: STEP 4 ( JAMA , 2021). Please read it before posting; the…
|
+24 | 28 | 3.5k | 2d |
|
Coming back to: Why a preprint's supplementary material is often the best part
Why a preprint's supplementary material is often the best part — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 ( N Engl J Med , 2021) with STEP 4 (…
|
+109 | 116 | 36k | 2d |
|
Revisiting: Journal club: SURMOUNT-1, read without the press release
On the subject in the title: Revisiting: Journal club: SURMOUNT-1, read without the press release Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…
|
+54 | 62 | 1.5k | 26d |
|
Journal club: STEP 3 and the intensive behavioural therapy floor
Posting this under the heading it deserves: Journal club: STEP 3 and the intensive behavioural therapy floor Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with STEP 4 (…
|
+6 | 10 | 13k | 28d |
|
Journal club: SELECT, absolute risk, and how it was reported
Journal club: SELECT, absolute risk, and how it was reported Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med , 2024). Please read…
|
2 | 52k | 1mo | |
|
Second pass at: A pooled estimate that changed when one trial was added
On the subject in the title: Second pass at: A pooled estimate that changed when one trial was added Working notes rather than a conclusion. Session topic: SELECT ( N Engl J Med , 2023). Please read it before…
|
+26 | 30 | 22k | 1mo |
|
Journal club: SELECT, absolute risk, and how it was reported — a second dataset
On the subject in the title: Journal club: SELECT, absolute risk, and how it was reported — a second dataset Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SELECT ( N…
|
4 | 1.3k | 1mo | |
|
How this community labels and discusses unrefereed work — the long version
Asking directly, because I could not find a straight answer: How this community labels and discusses unrefereed work — the long version I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited in support of a…
|
+18 | 23 | 21k | 2mo |
|
The "under review" status pill and when a moderator applies it
Posting this under the heading it deserves: The "under review" status pill and when a moderator applies it Everything below is what sits behind that. Session topic: SURMOUNT-4 ( JAMA , 2024). Please read it…
|
+96 | 119 | 17k | 3mo |
|
Coming back to: Measurement error in a self-reported exposure
Measurement error in a self-reported exposure — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…
|
+23 | 27 | 49k | 3mo |
Sponsored
Janoshik Analytical — independent third-party testingHPLC purity and mass-spectrometric identity on submitted samples, reported with the method stated. The laboratory most often cited in this community’s verification records.Independent testing →
Sponsored
GL Biochem (Shanghai) Ltd. — synthesis, directFounded 1998. ISO 9001 and cGMP certified, over 1,500 staff and 200-plus patents. Custom peptide synthesis and amino acid derivatives, with a batch certificate on every order.Custom synthesis →